This user has not added any information to their profile yet.
I received broad training, from clinical medicine (an M.D. degree from the top medical school in China, Beijing University) to biochemistry and molecular biology (a Ph.D. in biochemistry and molecular biology from University of North Carolina at Chapel Hill, under the mentorship of Dr. Mary Sue Coleman) to mouse and human genetics (post-doctoral training under the guidance of Dr. Oliver Smithies, a 2007 Nobel Laureate for the invention of gene targeting and mouse knockout technologies). In addition, I have gained significant research and administration experience in my role as Associate Director, then as Director, of the Gene Targeting Core Facility at University of Iowa for almost 20 years. Over this period, the core generated more than more than $5 million in revenue, secured more than $50 million funding from various sources, including NIH, HHMI, NSF, and many foundations, and created more than 75 lines of knockout mice. While carrying out my duties as the Director of the Gene Targeting Core Facility, I simultaneously served as the Director of the Research Division, in the department of Ob-Gyn, where I expanded my research program to genetic and cell biology studies of gynecologic cancer, including endometrial, ovarian, and breast cancers. In 2014, with three colleagues from the University of Iowa, I formed Immortagen with the goal of seeking to personalize cancer treatment through revolutionary clinical decision support algorithms. I also went through the intensive training of the Venture School at the John Pappajohn Entrepreneurial Center at the University of Iowa to better prepare myself with the real-world experimentation and mentorship, not only in startup but in business in general. Leveraging my experience as a Director of a core facility and my broad training in genetics, molecular and cellular biology and physiology, I currently serve as the Director for Product Development at Immortagen. In this role, I work to ensure product development and commercialization of predictive algorithms for cancer.